Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tertomotide - KAEL-GemVax

Next Previous
Drug Profile

Tertomotide - KAEL-GemVax

Alternative Names: GV1001®; hTERT RNA vaccine - KAEL-GemVax; LucaVax; RIAVAX; Telomerase peptide vaccine - KAEL-GemVax; TeloVac; Tertomotide HCl

Latest Information Update: 16 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pharmexa
  • Developer Affitech A/S; Cancer Research UK; KAEL-GemVax; Lytix Biopharma; Norwegian Radium Hospital; Pharmexa
  • Class Alzheimer vaccines; Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pancreatic cancer
  • Phase III Benign prostatic hyperplasia
  • Phase II Alzheimer's disease; Colorectal cancer; Non-small cell lung cancer; Progressive supranuclear palsy
  • Phase I/II Malignant melanoma
  • No development reported Solid tumours
  • Discontinued Liver cancer

Most Recent Events

  • 02 Nov 2023 Gemvax completes application as an orphan drug for tertomotide to the Korea Orphan and Essential Drugs Center before November 2023
  • 02 Nov 2023 Gemvax announces intention to submit a conditional NDA for tertomotide in progressive supranuclear palsy in South Korea
  • 02 Nov 2023 Efficacy data from a phase III trial in Pancreatic cancer released by Gemvax
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top